Fluocinonide

CHEMBL1501 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
494.5 g/mol
LogP
3.2
Phase
4

This high-potency topical corticosteroid is used to relieve the inflammation, itching, and scaling associated with skin conditions such as psoriasis, eczema, and contact dermatitis. It should be applied sparingly and for limited periods to minimize the risk of skin thinning and other side effects.

Khối lượng phân tử

494,5000 g/mol

LogP

3,20

TPSA

99,10 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C

InChI

InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1

Molecular Formula

C26H32F2O7

HBD / HBA

1 / 9

Liên kết có thể quay

4

Nguyên tử nặng

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This high-potency topical corticosteroid is used to relieve the inflammation, itching, and scaling associated with skin conditions such as psoriasis, eczema, and contact dermatitis. It should be applied sparingly and for limited periods to minimize the risk of skin thinning and other side effects.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Fluocinonide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1501. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9642. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.